Elicio TherapeuticsFRA:9HA 10 EV-to-FCF is -1.40 as of Jul. 08, 2026. GuruFocus rates FRA:9HA with a GF Score™ of 10/100. The stock has 1 warning sign investors should review. Among 327 Biotechnology companies, Elicio Therapeutics ranks worse than 305810.09% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Elicio Therapeutics's Enterprise Value is €46.39 Mil.
Elicio Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-33.08 Mil. Therefore, Elicio Therapeutics's EV-to-FCF for today is -1.40.
The historical rank and industry rank for Elicio Therapeutics's EV-to-FCF or its related term are showing as below:
FRA:9HA'
s EV-to-FCF Range Over the Past 10 Years
Min: -1.37 Med: 0 Max: 0
Current: -1.37
FRA:9HA's EV-to-FCF is ranked worse than 100% of 327
companies
in the Biotechnology industry
Industry Median: 16.69
vs FRA:9HA: -1.37
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Elicio Therapeutics's PE Ratio (TTM) for today is calculated as:
Elicio Therapeutics's share price for today is €2.80.
Elicio Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.063.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Elicio Therapeutics EV-to-FCF Related Terms
Elicio Therapeutics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Elicio Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Elicio Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elicio Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Elicio Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Elicio Therapeutics's EV-to-FCF falls into.
Elicio Therapeutics's current Enterprise Value is €46.39 Mil.
Elicio Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-33.08 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elicio Therapeutics (FRA:9HA) has a EV-to-FCF of -1.40 as of Jul. 08, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Elicio Therapeutics and its competitors. According to the industry distribution chart, Elicio Therapeutics ranks #999999 out of 327 companies in the Biotechnology industry.
Is Elicio Therapeutics' EV-to-FCF too high?
Elicio Therapeutics' current EV-to-FCF is -1.40. Based on the distribution chart, Elicio Therapeutics ranks #999999 out of 327 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Elicio Therapeutics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Elicio Therapeutics' EV-to-FCF compare to GOSS and GANX?
According to the Biotechnology industry distribution chart, Elicio Therapeutics ranks #999999 out of 327 companies for EV-to-FCF. This places Elicio Therapeutics in the lower half of its industry. The industry median EV-to-FCF is 16.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.69, based on 327 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Elicio Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elicio Therapeutics's current EV-to-FCF is -1.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elicio Therapeutics stock overvalued right now?
Elicio Therapeutics (FRA:9HA) has a current EV-to-FCF of -1.40. The current EV-to-FCF is -1.40. Elicio Therapeutics' overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Elicio Therapeutics (FRA:9HA), the current EV-to-FCF is -1.40 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
10GF Score
Get the complete analysis for FRA:9HA
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9HA has been successfully added to your 
